A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response*
|
|
- Hilda McDonald
- 6 years ago
- Views:
Transcription
1 Arch Womens Ment Health (2003) 6: DOI /s Short communication A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response* T. Pearlstein 1, E. Spurell 1, L. A. Hohlstein 1, V. Gurney 2, J. Read 1, C. Fuchs 3, and M. B. Keller 1 1 Department of Psychiatry and Human Behavior, Brown Medical School, Providence, RI, U.S.A. 2 Laurel Hill Inn Residential Eating Disorder Program, Medford, MA, U.S.A. 3 Boston, MA, U.S.A. Received August 7, 2002; accepted January 26, 2003 Published online April 23, 2003 Springer-Verlag 2003 Summary Twenty subjects with binge eating disorder were randomly assigned to flexible-dose fluvoxamine or placebo for 12 weeks. A significant reduction in binge frequency, Beck Depression Inventory scores and the eating concern, shape concern and weight concern subscales of the Eating Disorder Examination were noted for both fluvoxamine (n 9) and placebo (n 11) groups. There were no significant differences between fluvoxamine and placebo for any treatment outcome variables. The findings from this small trial contribute to the inconsistent results of antidepressant studies in binge eating disorder. Keywords: Binge eating disorder; fluvoxamine; placebo. Introduction Binge eating disorder (BED) is characterized by repeated episodes of eating large quantities of food while experiencing a sense of loss of control, without compensatory measures such as excessive food restriction, excessive exercise, vomiting or laxative abuse. The number of antidepressant treatment trials conducted in BED is small to date, and the results have been mixed. Three randomized, double-blind, placebo-controlled (DBPC) trials with selective serotonin reuptake inhibitors (SSRIs) have reported significantly decreased binge eating and weight with fluoxetine (Arnold et al., 2002), sertraline (McElroy * This study was presented as a poster at the 9 th International Conference on Eating Disorders, May, 2000, New York, NY. Supported in part by a grant from Solvay Pharmaceuticals. et al., 2000) and fluvoxamine (Hudson et al., 1998). Early DBPC trials reported significant reduction of binge eating with desipramine (McCann and Agras, 1990) but not imipramine (Alger et al., 1991). An open trial reported that fluvoxamine and fluoxetine did not decrease binge eating or weight (Ricca et al., 2001), while a case series suggested efficacy for venlafaxine (Malhotra et al., 2002). The efficacy of combined antidepressant medication and therapy or weight management has also yielded mixed reports. Positive reports of weight reduction have been reported in placebo-controlled trials of imipramine with diet counseling/psychological support (Laederach-Hofmann et al., 1999) and fluoxetine with behavior therapy (Marcus et al., 1990) and in open trials of fluoxetine and phentermine with cognitive behavioral therapy (CBT) (Devlin et al., 2000) and of fluvoxamine or fluoxetine with CBT (Ricca et al., 2001). However, fluvoxamine did not enhance weight loss when added to nutritional management or CBT (de Zwann et al., 1992). Treatment recommendations for BED are difficult to determine since many of the antidepressant treatment studies involve short-term treatment and high placebo response rates (Devlin, 2001). This study was expected to replicate the findings of the previous DBPC fluvoxamine trial, which showed significant reductions in binge eating and weight over 9 weeks. The current study was longer
2 148 T. Pearlstein et al. (12 weeks) in duration and used the Eating Disorder Examination (EDE, Cooper and Fairburn, 1987) to classify binge episodes at pre- and post-treatment instead of food logs. Another aim of the present study was to see if fluvoxamine led to a significant reduction in associated eating disorder psychopathology as measured by the eating disorder subscales of the EDE. Patients and methods Subjects were recruited by media advertisement and by referral from health professionals. Twenty-five subjects who met DSM-IV research criteria for BED signed institutionally-approved informed consent forms. Twenty subjects (17 women and 3 men) completed the protocol. The mean age of subjects was 41. Ninety percent were Caucasian, 70% were currently married, and 90% were employed. The average pretreatment Body Mass Index was for all subjects. All subjects underwent two intake assessment sessions scheduled one week apart. During the first, the diagnosis of BED was confirmed using the EDE (Cooper and Fairburn, 1987), adapted for the BED diagnosis by including additional questions to meet DSM-IV criteria. The EDE has demonstrated ability to distinguish BED individuals from individuals with other eating disorders and from overweight individuals without an eating disorder (Wilfley et al., 2000). The EDE was administered by the second, fourth, and fifth authors. The second author had been trained by one of the developers of the interview (Fairburn), had met his standards of reliability, and had extensive experience training others to deliver the EDE. Training and administration of the other interviewers was in accordance with recommended standards of training (Cooper and Fairburn, 1987). Meetings were held regularly to discuss and review ratings, particularly those of binge episodes. Following the EDE, subjects were instructed in the filling out of food logs, and these were completed daily throughout the study. Although subjects completed food logs, the EDE binge rating was used as an outcome measure rather than self-reported binge episodes. The EDE classification of binge episodes is highly correlated with self-report binge episodes from food logs (Rosen et al., 1990), and is generally regarded to be the optimal method of assessment for eating disorders (Smith et al., 1994; Wilfley et al., 1997; Wilson, 1993). At the second intake assessment, the Structured Clinical Interview for DSM-IV (SCID, Spitzer et al., 1990), the Hamilton Depression Scale (HAM-D, Hamilton, 1960) and the Clinical Global Impression Scale (CGI, Guy, 1976) were administered, and subjects completed self-report measures including the Hopkins Symptom Checklist (SCL-90, Derogatis, 1977) and the Beck Depression Inventory (BDI, Beck, 1978). Subjects received one week of single-blind placebo, and were then randomized to flexible dose fluvoxamine (titrated up to 150mg b.i.d.) or placebo for 12 weeks. Subjects were instructed not to participate in psychotherapy or a weight reduction program during the trial. Subjects met with a research nurse and the psychiatrist weekly for the first 6 weeks of the protocol and then biweekly for the remaining 6 weeks. At each visit, food logs were collected, vital signs and adverse events were monitored, psychoeducational materials on healthy eating were distributed, and study medication was dispensed, the dose determined by response and tolerability. During the twelfth week, subjects again received the EDE interview and HAM-D by the blinded psychologist who performed the pre-treatment EDE. Subjects completed self-report questionnaires, and a blinded study nurse administered the CGI. Following completion of the 12 weeks of double-blind medication, all subjects were offered continued treatment determined by response and clinical status. Results The primary outcome variables included binge eating frequency, the four subscale scores from the EDE (restraint, eating concern, shape concern, and weight concern), weight, HAM-D, CGI, SCL-90 and BDI. At baseline the treatment groups were comparable with respect to age, sex, number of days they had a binge episode in the past month, associated eating disorder psychopathology (EDE subscale scores), weight, and level of depression from the HAM-D, SCL-90, and BDI. There were no significant differences between the two groups on any of the variables except a trend (p 0.06, independent samples t-test, two-tailed) for subjects in the placebo group to have a higher pre-treatment binge frequency. Repeated measures ANOVAs were conducted to determine if the treatment group showed a greater reduction on the outcome variables following the 12-week trial. A significant reduction in binge frequency, SCL-90 and BDI scores, and the eating concern, shape concern and weight concern subscales of the EDE were noted for both the fluvoxamine (n 9) and placebo (n 11) groups (See Table 1). Fifty percent of subjects in both groups were free of binge eating by the end of the study. There were no significant differences between fluvoxamine and placebo for any of the treatment outcome variables. Thus, while both groups showed significant improvement at post-treatment, the medication group did not show any greater improvement than the placebo group on any assessment. A blinded rating of any improvement (CGI-I 1, 2 or 3) at 12 weeks was obtained on all of the subjects who received fluvoxamine (9/9) and 7 of the 11 subjects who received placebo, while the 4 subjects who were rated as having made no improvement (CGI-I 4) were all in the placebo group; this difference approached significance (Pearson s Chi-Squre 4.09; p 0.07). The average dose achieved (administered b.i.d.) was 239mg/day in the fluvoxamine group and 264mg/ day in the placebo group. Side effects that were reported by 3 or more subjects included sedation (8 on fluvoxamine, 3 on placebo), nausea (4 on fluvoxamine, 1 on placebo), dry mouth (4 on fluvoxamine, 3 on placebo), and decreased libido (3 on
3 Fluvoxamine in binge eating disorder 149 Table 1. Repeated measures for treatment and placebo groups at pre- and post-treatment Variable n Mean (SD) Mean (SD) F 1 : Main F 2 : Interaction effect of pre-treat post-treat effect of time group X time Number of days with binges 41.30** 0.08 in the past 28 days Placebo group (6.21) 7.31 (9.31) Treatment group (55.68) 3.11 (4.20) Restraint subscale 3.78# 2.12 Placebo group (1.08) 1.45 (0.98) Treatment group (1.24) 0.91 (0.78) Eating concern subscale 22.60** 1.67 Placebo group (1.02) 0.44 (0.55) Treatment group (0.96) 0.31 (0.39) Shape concern subscale 32.18** 0.05 Placebo group (0.43) 2.50 (1.15) Treatment group (0.74) 2.24 (0.85) Weight concern subscale 17.32** 0.46 Placebo group (0.94) 2.36 (1.07) Treatment group (0.49) 2.40 (1.22) Weight Placebo group (96) 262 (99) Treatment group (85) 242 (82) Beck * 4.02# Placebo group (0.57) 0.37 (0.26) Treatment group (0.22) 0.32 (0.30) Hamilton Placebo group (12.40) 7.38 (6.16) Treatment group (9.22) 9.38 (9.71) SCL ** 0.91 Placebo group (0.55) 0.40 (0.29) Treatment group (0.33) 0.30 (0.29) Note: F 1 indicates the main effect for the entire sample, F 2 indicates the effect when examining a difference for the two groups. # p 0.10; * p 0.01; ** p : The Beck scores are presented as means instead of a total summed score to eliminate the bias of a few subjects who failed to answer items on their questionnaires fluvoxamine, 0 on placebo). The 5 subjects who did not complete the protocol withdrew consent due to lack of response (n 1), hospitalization due to an amnestic event (n 1), nausea and anxiety (n 1), knee surgery and inability to keep appointments (n 1), and moving out of state (n 1). Discussion In this study of 20 subjects with BED, both fluvoxamine and placebo were associated with decreased binge eating, eating disorder psychopathology and mood and anxiety symptoms. More than 50% of the total sample was binge free at the end of 12 weeks. The high placebo response may be accounted for by the increased awareness and control over the binge eating due to the thorough pre-treatment assessment, the keeping of daily food logs, and the regular clinical assessments during the study. None of the subjects in this study had previous treatment for an eating disorder, and the 3 5 hours of pretreatment assessment (including the SCID and EDE), may have served as a treatment intervention. The food logs were collected and reviewed briefly with the subject at each visit, and this form of self-monitoring may have served as a treatment component. Selfmonitoring alone has been demonstrated to be an effective intervention for weight loss (Foreyt and Goodrick, 1994). Even though subjects received minimal standardized psychoeducational material at each visit, subjects had weekly or biweekly visits with a nurse and a psychiatrist, and this may also have increased subject s motivation and sense of support to gain control over their eating. The results of the current study are similar to the results of a randomized, parallel series, open study
4 150 T. Pearlstein et al. of 108 BED subjects that reported that neither fluvoxamine 300mg/day or fluoxetine 60mg/day were effective in reducing weight, binge eating, or eating attitudes and behaviors after 24 weeks of treatment or at one year follow-up compared to baseline (Ricca et al., 2001). Similar to the current study, Ricca and colleagues used the EDE as an assessment and treatment outcome measure. The results of the current study contradict the results of the previously published DBPC studies with SSRIs. Hudson and colleagues (1998) administered flexible-dose fluvoxamine (average dose 260mg/day) or placebo to 85 BED subjects for 9 weeks. Fluvoxamine was superior to placebo in decreasing binge eating, body weight and improving outcome as measured by the CGI scale. Flexible-dose sertraline (average dose 187mg/day) in 34 subjects (McElroy et al., 2000) and flexible-dose fluoxetine (average dose 71mg/day) in 60 subjects (Arnold et al., 2002) were both superior to placebo after 6 weeks on the same outcome measures. These three studies also demonstrated substantial placebo response rates. However, the EDE, which may provide more accurate ratings for binge episodes, was not used in these three studies, and the higher placebo response rate and lack of drug-placebo difference in the current study may have been due in part to the more in-depth assessment interview with the EDE. It is of interest that the only subjects who did not improve at all during the study were all in the placebo group. The major limitations of this study were the small sample size and the inclusion of potential confounding nonspecific treatment components, i.e., rigorous assessment, self-monitoring and frequent clinical contact. The results of this small study contribute to the contradictory efficacy literature of antidepressant treatment trials for BED. It will be helpful in future studies to include larger samples and a longer period of clinical treatment to decrease the contribution of the high placebo response rates in BED. References Alger SA, Schwalberg MD, Bigaouette JM, Michalek AV, Howard LJ (1991) Effects of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects. Am J Clin Nutr 53: Arnold LM, McElroy SL, Hudson JI, Welge JA, Bennett AJ, Keck PE (2002) A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. J Clin Psychiatry 63: Beck AT (1978) Beck Depression Inventory. Center for Cognitive Therapy, Philadelphia, PA. Cooper Z, Fairburn CB (1987) The Eating Disorder Examination: A semi-structured interview for the assessment of the specific psychopathology of eating disorders. Int J Eat Disord 6: 1 8. Derogatis L (1977) SLC-90 administration, scoring, and procedures manual-i. Johns Hopkins University, Baltimore. de Zwaan M, Nutzinger DO, Schoenbeck G (1992) Binge eating in overweight women. Compr Psychiatry 33: Devlin MJ (2001) Binge-eating disorder and obesity: A combined treatment approach. Psychiatr Clin North Am 24: Devlin MJ, Goldfein JA, Carino JS, Wolk SL (2000) Open treatment of overweight binge eaters with phentermine and fluoxetine as an adjunct to cognitive-behavioral therapy. Int J Eat Disord 28: Foreyt JP, Goodrick GK (1994) Attributes of successful approaches to weight loss and control. Appl Prev Psychol 3: Guy W (1976) Clinical Global Impressions. In ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare publication (ADM) , National Institute of Mental Health, Rockville, MD, pp Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg 23: Hudson JI, McElroy SL, Raymond NC, Crow S, Keck PE, Carter WP, Mitchell JE, Strakowski SM, Pope HG, Coleman BS, Jonas JM (1998) Fluvoxamine in the treatment of binge-eating disorder: A multicenter placebo-controlled, double-blind trial. Am J Psychiatry 155: Laederach-Hofmann K, Graf C, Horber F, Lippuner K, Lederer S, Michel R, Schneider M (1999) Imipramine and diet counseling with psychological support in the treatment of obese binge eaters: A randomized, placebo-controlled double-blind study. Int J Eat Disord 26: Malhotra S, King KH, Welge JA, Brusman-Lovins L, McElroy SL (2002) Venlafaxine treatment of binge-eating disorder associated with obesity: A series of 35 patients. J Clin Psychiatry 63: Marcus MD, Wing RR, Ewing L, Kern E, McDermott M, Gooding W (1990) A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese bingeeaters and non-binge eaters. Am J Psychiatry 147: McCann UD, Agras WS (1990) Successful treatment of nonpurging bulimia nervosa with desipramine: A double-blind, placebo-controlled study. Am J Psychiatry 147: McElroy SL, Casuto LS, Nelson EB, Lake KA, Soutullo CA, Keck PE, Hudson JI (2000) Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry 157: Ricca V, Mannucci E, Mezzani B, Moretti S, DiBernardo M, Bertelli M, Rotella CM, Faravelli C (2001) Fluoxetine and fluvoxamine combined with individual cognitive-behavior therapy in binge eating disorder: a one-year follow-up study. Psychother Psychosom 70: Rosen JC, Vara L, Wendt S, Leitenberg H (1990) Validity studies of the Eating Disorder Examination. Int J Eat Disord 9: Smith DE, Marcus MD, Eldredge KL (1994) Binge eating syndromes: A review of assessment and treatment with an emphasis on clinical application. Behav Ther 25: Spitzer R, Williams J, Gibbon M, First M (1990) Structured Clinical Interview for DSM-III-R. American Psychiatric Press, Washington, D.C.
5 Fluvoxamine in binge eating disorder 151 Wilfley DE, Schwartz MB, Spurrell EB, Fairburn CG (1997) Assessing the specific psychopathology of binge eating disorder patients: Interview or self-report? Behav Res Ther 35: Wilfley DE, Schwartz MB, Spurrell EB, Fairburn CG (2000) Using the Eating Disorder Examination to identify the specific psychopathology of binge eating disorder. Int J Eat Disord 27: Wilson GT (1993) Assessment of binge eating. In: Fairburn CG, Wilson GT (eds), Binge eating: Nature, assessment and treatment. Guilford Press, New York, pp Correspondence: Teri Pearlstein, M.D., Assistant Professor, Department of Psychiatry and Human Behavior, Brown Medical School, Director, Women s Behavioral Health Program, Women and Infants Hospital, 101 Dudley Street, Providence, RI 02905, U.S.A.; Teri_Pearlstein@brown.edu
6
Review and Meta-analysis of Pharmacotherapy for Binge-eating Disorder
intervention AND prevention nature publishing group Review and Meta-analysis of Pharmacotherapy for Binge-eating Disorder Deborah L. Reas 1,2 and Carlos M. Grilo 3,4 This study evaluated available controlled
More informationTreatment of Obese Binge Eater
Treatment of Obese Binge Eater Jung Hyun Lee, M.D. Treatment of Obese Binge Eater Email : docljh@empal.com Abstract It is now widely recognized that there is a subgroup of obese individuals with a significantly
More informationEffects of milnacipran on binge eating a pilot study
ORIGINAL RESEARCH Effects of milnacipran on binge eating a pilot study Shun ichi Noma 1 Teruhisa Uwatoko 1 Haruka Yamamoto 2 Takuji Hayashi 1 1 Department of Psychiatry, Graduate School of Medicine, Kyoto
More informationDoes Interpersonal Therapy Help Patients With Binge Eating Disorder Who Fail to Respond to Cognitive-Behavioral Therapy?
Journal of Consulting and Clinical Psychology 1995, Vol. 63, No. 3, 356-360 Copyright 1995 by the American Psychological Association, Inc. 0022-006X/95/S3.00 Does Interpersonal Therapy Help Patients With
More informationNIH Public Access Author Manuscript Arch Gen Psychiatry. Author manuscript; available in PMC 2013 August 30.
NIH Public Access Author Manuscript Published in final edited form as: Arch Gen Psychiatry. 2010 January ; 67(1): 94 101. doi:10.1001/archgenpsychiatry.2009.170. Psychological Treatments of Binge Eating
More informationAuthor Manuscript Expert Opin Emerg Drugs. Author manuscript; available in PMC 2015 March 01.
NIH Public Access Author Manuscript Published in final edited form as: Expert Opin Emerg Drugs. 2014 March ; 19(1): 99 142. doi:10.1517/14728214.2014.879291. Current and Emerging Drug Treatments for Disorder
More informationThe Current Status of Treatment for Anorexia Nervosa and Bulimia Nervosa
The Current Status of Treatment for Anorexia Nervosa and Bulimia Nervosa David B. Herzog Martin B. Keller Michael Strober Christine Yeh Sung-Yun Pai (Accepted 1 March 1991) A survey investigating the current
More informationChapter 2. Binge Eating Disorder: A review. Alexandra Dingemans Tijs Bruna Eric van Furth
Chapter 2 Binge Eating Disorder: A review Alexandra Dingemans Tijs Bruna Eric van Furth This Chapter was preciously published in International Journal of Obesity & Related Metabolic Disorders 2001; 29,
More informationORIGINAL ARTICLE. is characterized by frequent
ORIGINAL ARTICLE A Randomized Comparison of Group Cognitive-Behavioral Therapy and Group Interpersonal Psychotherapy for the Treatment of Overweight Individuals With Binge-Eating Disorder Denise E. Wilfley,
More informationNIH Public Access Author Manuscript J Consult Clin Psychol. Author manuscript; available in PMC 2013 October 01.
NIH Public Access Author Manuscript Published in final edited form as: J Consult Clin Psychol. 2012 October ; 80(5): 897 906. doi:10.1037/a0027001. Predictors and Moderators of Response to Cognitive Behavioral
More informationMindfulness Action-Based Cognitive Behavioural Therapy for Concurrent Binge Eating Disorder and Substance Use Disorders
Mindfulness Action-Based Cognitive Behavioural Therapy for Concurrent Binge Eating Disorder and Substance Use Disorders Leah Shapira, M.A. Christine M. Courbasson, Ph.D., C.Psych Yasunori Nishikawa, Hon.
More informationTitle: Group therapy for binge eating in type 2 diabetes: A randomized trial.
Group Treatment of Binge Eating 1 Title: Group therapy for binge eating in type 2 diabetes: A randomized trial. Authors: J. Kenardy 1, M. Mensch 2, K. Bowen 2, B. Green 2, J. Walton 2 Departments: 1 School
More informationBinge Eating Disorder Diagnosis and Treatment Options
DISEASE MANAGEMENT CNS Drugs 1999 May; 11 (5): 351-361 1172-7047/99/0005-0351/$05.50/0 Adis International Limited. All rights reserved. Binge Eating Disorder Diagnosis and Treatment Options Timothy D.
More informationAn Exploratory Study of a. Meditation-Based Intervention. for Binge Eating Disorder. Jean L. Kristeller and C. Brendan Hallett. Dept.
1 An Exploratory Study of a Meditation-Based Intervention for Binge Eating Disorder Jean L. Kristeller and C. Brendan Hallett Dept. of Psychology Indiana State University Journal of Health Psychology.
More information#CHAIR2015. Miami, Florida. September 24 26, JW Marriott Miami. Sponsored by
#CHAIR2015 September 24 26, 2015 JW Marriott Miami Miami, Florida Sponsored by Binge Eating Disorders Mark S. Gold, MD RiverMend Health Ponte Vedra Beach, FL University of Florida Gainesville, FL Mark
More informationREVIEW Two forms of disordered eating in obesity: binge eating and night eating
(2003) 27, 1 12 ß 2003 Nature Publishing Group All rights reserved 0307 0565/03 $25.00 www.nature.com/ijo REVIEW Two forms of disordered eating in obesity: binge eating and night eating Albert J Stunkard*
More informationPharmacotherapy for Patients With Eating Disorders
2005 Psychiatric Times. All rights reserved. Pharmacotherapy for Patients With Eating Disorders by Timothy D. Brewerton, M.D. Psychiatric Times May 2004 Vol. XXI Issue 6 Eating disorders, including anorexia
More informationSocial anxiety and self-consciousness in binge eating disorder: associations with eating disorder psychopathology
Available online at www.sciencedirect.com Comprehensive Psychiatry xx (2011) xxx xxx www.elsevier.com/locate/comppsych Social anxiety and self-consciousness in binge eating disorder: associations with
More informationFrequency of Binge Eating Episodes in Bulimia Nervosa and Binge Eating Disorder: Diagnostic Considerations
SPECIAL SECTION REVIEW ARTICLE Frequency of Binge Eating Episodes in Bulimia Nervosa and Binge Eating Disorder: Diagnostic Considerations G. Terence Wilson, PhD 1 * Robyn Sysko, PhD 2 ABSTRACT Objective:
More informationBINGE EATING disorder is a
Risk Factors for Binge Eating Disorder A Community-Based, Case-Control Study ORIGINAL ARTICLE Christopher G. Fairburn, DM, MPhil, FRCPsych; Helen A. Doll, MSc; Sarah L. Welch, DPhil, MRCPsych; Phillipa
More informationEating Disorders: Clinical Features, Comorbidity, and Treatment
Eating Disorders: Clinical Features, Comorbidity, and Treatment Carol B. Peterson, PhD Associate Professor Eating Disorders Research Program Department of Psychiatry University of Minnesota peter161@umn.edu
More informationMild, moderate, meaningful? Examining the psychological and functioning correlates of DSM-5 eating disorder severity specifiers
Received: 9 August 2016 Revised: 14 April 2017 Accepted: 17 April 2017 DOI: 10.1002/eat.22728 ORIGINAL ARTICLE Mild, moderate, meaningful? Examining the psychological and functioning correlates of DSM-5
More informationORIGINAL ARTICLE. A Multicenter Comparison of Cognitive-Behavioral Therapy and Interpersonal Psychotherapy for Bulimia Nervosa
ORIGINAL ARTICLE A Multicenter Comparison of Cognitive-Behavioral Therapy and Interpersonal Psychotherapy for Bulimia Nervosa W. Stewart Agras, MD; B. Timothy Walsh, MD; Christopher G. Fairburn, MD; G.
More informationLong-term efficacy of psychological treatments for binge eating disorder
The British Journal of Psychiatry (212) 2, 232 237. doi: 1.1192/bjp.bp.11.894 Long-term efficacy of psychological treatments for binge eating disorder Anja Hilbert, Monica E. Bishop, Richard I. Stein,
More informationAre psychological treatments of panic disorder efficacious?
Are psychological treatments of panic disorder efficacious? Peter Wilhelm 7.3.2018 PD Dr. Peter Wilhelm, Spring 2018 1 Efficacy of Behavioral Treatment of Panic Disorder First randomised controlled trial
More informationThe delineation of patient characteristics that usefully
Article Outcome Predictors for the Cognitive Behavior Treatment of Bulimia Nervosa: Data From a Multisite Study W. Stewart Agras, M.D. Scott J. Crow, M.D. Katherine A. Halmi, M.D. James E. Mitchell, M.D.
More informationComparison of Different Antidepressants and Psychotherapy in the Short-term Treatment of Depression
ORIGINAL COMPARISON PAPER OF DIFFERENT ANTIDEPRESSANTS AND PSYCHOTHERAPY IN THE SHORT-TERM TREATMENT OF DEPRESSION Comparison of Different Antidepressants and Psychotherapy in the Short-term Treatment
More informationEffectiveness of cognitive behavioural psychotherapy alone and combined with pharmacotherapy in binge eating disorder: a differential research.
BJMP 2014;7(3):a724 Research Article Effectiveness of cognitive behavioural psychotherapy alone and combined with pharmacotherapy in binge eating disorder: a differential research. Lanzarone Cristina,
More informationComparison of Patients With Bulimia Nervosa, Obese Patients With Binge Eating Disorder, and Nonobese Patients With Binge Eating Disorder
ORIGINAL ARTICLES Comparison of Patients With Bulimia Nervosa, Obese Patients With Binge Eating Disorder, and Nonobese Patients With Binge Eating Disorder Declan T. Barry, PhD, Carlos M. Grilo, PhD, and
More informationDeveloping a new treatment approach to binge eating and weight management. Clinical Psychology Forum, Number 244, April 2013.
Developing a new treatment approach to binge eating and weight management Clinical Psychology Forum, Number 244, April 2013 Dr Marie Prince 1 Contents Service information Binge Eating Disorder Binge Eating
More informationMaintenance Treatment for Anorexia Nervosa: A Comparison of Cognitive Behavior Therapy and Treatment as Usual
REGULAR ARTICLE Maintenance Treatment for Anorexia Nervosa: A Comparison of Cognitive Behavior Therapy and Treatment as Usual Jacqueline C. Carter, PhD 1,2 * Traci L. McFarlane, PhD 1,2 Carmen Bewell,
More informationEating Disorders Detection and Treatment. Scott Crow, M.D. Professor of Psychiatry University of Minnesota Chief Research Officer The Emily Program
Eating Disorders Detection and Treatment Scott Crow, M.D. Professor of Psychiatry University of Minnesota Chief Research Officer The Emily Program Obesity Trends* Among U.S. Adults BRFSS, 1990, 1995, 2005
More informationLindsey Dorflinger, Ph.D. VA Connecticut Healthcare System Yale School of Medicine
Lindsey Dorflinger, Ph.D. VA Connecticut Healthcare System Yale School of Medicine Acknowledgments Robin Masheb, PhD Carlos Grilo, PhD Barbara Rolls, PhD Diane Mitchell, MS, RD No conflicts of interest
More informationSupplementary Online Content
Supplementary Online Content Lam RW, Levitt AJ, Levitan RD, et al. Efficacy of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder: a randomized
More informationPsychological, pharmacological, and combined treatments for binge eating disorder: a systematic review and metaanalysis
Psychological, pharmacological, and combined treatments for binge eating disorder: a systematic review and metaanalysis Ata Ghaderi 1, Jenny Odeberg 2, Sanna Gustafsson 3,4, Maria Råstam 5,6, Agneta Brolund
More informationTHE ASSOCIATION BETWEEN PHYSICAL ACTIVITY AND BINGE EATING. Jill Nesbitt
THE ASSOCIATION BETWEEN PHYSICAL ACTIVITY AND BINGE EATING By Jill Nesbitt Submitted to the graduate degree program in Psychology and the Graduate Faculty of the University of Kansas in partial fulfillment
More informationShould binge eating disorder be included in the DSM-V? A critical review of the state of evidence.
Wesleyan University From the SelectedWorks of Ruth Striegel Weissman 2008 Should binge eating disorder be included in the DSM-V? A critical review of the state of evidence. Ruth Striegel Weissman Available
More informationLisdexamfetamine for Adults with Binge Eating Disorder
ISPUB.COM The Internet Journal of Psychiatry Volume 4 Number 1 Lisdexamfetamine for Adults with Binge Eating Disorder J R Scarff Citation J R Scarff. Lisdexamfetamine for Adults with Binge Eating Disorder.
More informationDSM-5 Reduces the Proportion of EDNOS Cases: Evidence from Community Samples
REGULAR ARTICLE DSM-5 Reduces the Proportion of EDNOS Cases: Evidence from Community Samples Paulo P.P. Machado, PhD 1 * Sónia Gonçalves, PhD 1 Hans W. Hoek, MD, PhD 2,3,4 ABSTRACT Objective: Eating Disorder
More informationThe Relationship of Weight Suppression and Dietary Restraint to Binge Eating in Bulimia Nervosa
REGULAR ARTICLE The Relationship of Weight Suppression and Dietary Restraint to Binge Eating in Bulimia Nervosa Michael R. Lowe, PhD 1 * J. Graham Thomas, BS 1 Debra L. Safer, MD 2 Meghan L. Butryn, PhD
More informationEating Disorders. Anorexia Nervosa. DSM 5:Eating Disorders. DSM 5: Feeding and Eating Disorders 9/24/2015
DSM 5: Feeding and Eating Disorders Eating Disorders Marsha D. Marcus, PhD The North American Menopause Society October 3, 2015 Feeding and Eating Disorders are characterized by a persistent disturbance
More informationEating Disorders in Youth
Eating Disorders in Youth Evaluating and Treating in the Medical Home February 27, 2017 Rebecca Marshall, MD, MPH Outline Anorexia Nervosa Bulimia Nervosa Binge Eating Disorder Avoidant Restrictive Food
More informationDiagnostic orphans for alcohol use disorders in a treatment-seeking psychiatric sample
Available online at www.sciencedirect.com Drug and Alcohol Dependence 96 (2008) 187 191 Short communication Diagnostic orphans for alcohol use disorders in a treatment-seeking psychiatric sample Lara A.
More informationRisk Factors and Patterns of Onset in Binge Eating Disorder
REGULAR ARTICLE Risk Factors and Patterns of Onset in Binge Eating Disorder Jamie L. Manwaring, MA 1 Anja Hilbert, PhD 2 Denise E. Wilfley, PhD 2,3,4,5* Kathleen M. Pike, PhD 6 Christopher G. Fairburn,
More informationOutline. Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly. Definitions
Outline Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly Michael E. Thase, MD Professor of Psychiatry Perelman School of Medicine University of Pennsylvania and Philadelphia
More informationExplanatory Attributions of Anxiety and Recovery in a Study of Kava
THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE Volume 10, Number 3, 2004, pp. 556 559 Mary Ann Liebert, Inc. Explanatory Attributions of Anxiety and Recovery in a Study of Kava KURIAN C. ABRAHAM,
More informationTaking Care: Child and Youth Mental Health TREATMENT OPTIONS
Taking Care: Child and Youth Mental Health TREATMENT OPTIONS Open Learning Agency 2004 TREATMENT OPTIONS With appropriate treatment, more than 80% of people with depression get full relief from their symptoms
More informationPUBLISHED VERSION. Copyright 1996 Cambridge University Press.
PUBLISHED VERSION Hay, P. J. ; Fairburn, C. G.; Doll, H. A. The classification of bulimic eating disorders: A community based study, Psychological Medicine, 1996; 26(4):801-812. Copyright 1996 Cambridge
More informationDSM-IV Threshold Versus Subthreshold Bulimia Nervosa
REGULAR ARTICLE DSM-IV Threshold Versus Subthreshold Bulimia Nervosa Daniel le Grange, PhD 1 * Roslyn B. Binford, PhD 1 Carol B. Peterson, PhD 2 Scott J. Crow, MD 2 Ross D. Crosby, PhD 3 Marjorie H. Klein,
More informationNIH Public Access Author Manuscript Curr Psychiatry Rep. Author manuscript; available in PMC 2012 September 05.
NIH Public Access Author Manuscript Published in final edited form as: Curr Psychiatry Rep. 2012 August ; 14(4): 432 446. doi:10.1007/s11920-012-0277-8. Psychological Treatments for Binge Eating Disorder
More informationA Comparison of Quality of Life in Obese Individuals with and without Binge Eating Disorder
REGULAR ARTICLE A Comparison of Quality of Life in Obese Individuals with and without Binge Eating Disorder Elizabeth Rieger, PhD 1 Denise E. Wilfley, PhD 2 * Richard I. Stein, PhD 3 Valentina Marino,
More informationTREATMENT OUTCOMES REPORT
TREATMENT OUTCOMES REPORT 2016 EDITION Helping patients, families and professionals understand treatment results Eating Recovery Center Treatment Outcomes Report, 2016 Edition Helping patients, families
More informationPsychological Versus Pharmacological Treatments of Bulimia Nervosa Predictors and Processes of Change
Page 1 of 16 Journal of Consulting and Clinical Psychology August 1999 Vol. 67, No. 4, 451-459 1999 by the American Psychological Association For personal use only--not for distribution. Psychological
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationAre Anti depressants Effective in the Treatment of Depressed Patients Who Do Not Seek Psychotherapy?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Are Anti depressants Effective in the
More informationState Self-Esteem Ratings in Women with Bulimia Nervosa and Bulimia Nervosa in Remission
REGULAR ARTICLE State Self-Esteem Ratings in Women with and in Remission Karen A. Daley, MPH, MS 1 David C. Jimerson, MD 2 Todd F. Heatherton, PhD 3 Eran D. Metzger, MD 2 Barbara E. Wolfe, PhD 1 * ABSTRACT
More informationBinge Eating Disorder and Body Uneasiness
Psychological Topics 17 (2008), 2, 287-312 Original Scientific Aricle UDC 616.89-088.441.42 613.25 Binge Eating Disorder and Body Uneasiness Massimo Cuzzolaro University Sapienza, Roma Rehabilitation Clinical
More informationEating patterns in patients with spectrum binge eating disorder
Wesleyan University From the SelectedWorks of Ruth Striegel Weissman 2011 Eating patterns in patients with spectrum binge eating disorder R H Striegel K Harvey F Rosselli G T Wilson L L Debar Available
More informationBehaviour Research and Therapy
Behaviour Research and Therapy 48 (2010) 187 193 Contents lists available at ScienceDirect Behaviour Research and Therapy journal homepage: www.elsevier.com/locate/brat The significance of overvaluation
More informationStudie 083 (950E-CNS )
Studie 083 (950E-CNS-0005-083) Studienberichtssynopse Clinical Study Report 950E-CNS-0005-083 EFFECTS OF THE USE OF REBOXETINE AS A SUBSTITUTE FOR SELECTIVE SEROTONIN REUPTAKE INHIBITOR ANTIDEPRESSANTS
More informationEating patterns in patients with spectrum binge eating disorder
Wesleyan University From the SelectedWorks of Ruth Striegel Weissman May, 2010 Eating patterns in patients with spectrum binge eating disorder Ruth Striegel Weissman Available at: https://works.bepress.com/ruth_striegel/54/
More informationConvergent Validity of a Single Question with Multiple Classification Options for Depression Screening in Medical Settings
DOI 10.7603/s40790-014-0001-8 Convergent Validity of a Single Question with Multiple Classification Options for Depression Screening in Medical Settings H. Edward Fouty, Hanny C. Sanchez, Daniel S. Weitzner,
More informationFibromyalgia is a chronic musculoskeletal disorder
A Randomized, -controlled, Double-blind, Flexible-dose Study of in the Treatment of Women with Fibromyalgia Lesley M. Arnold, MD, Evelyn V. Hess, MD, James I. Hudson, MD, SM, Jeffrey A. Welge, PhD, Sarah
More informationBody Dissatisfaction and Binge Eating in Obese Women: The Role of Restraint and Depression
Body Dissatisfaction and Binge Eating in Obese Women: The Role of Restraint and Depression Jane Wardle, Jo Waller, and Lorna Rapoport Abstract WARDLE, JANE, JO WALLER, AND LORNA RAPOPORT. Body dissatisfaction
More informationTreating Depression in Disadvantaged Women: What is the evidence?
Treating Depression in Disadvantaged Women: What is the evidence? Megan Dwight Johnson, MD MPH Associate Professor Medical Director, UWMC Inpatient Psychiatry Department of Psychiatry and Behavioral Sciences
More informationSupplemental Digital Content
PharmacoEconomics Do Productivity Costs Matter? The Impact of Including Productivity Costs on the Cost Effectiveness of Interventions Targeted at Depressive Disorders Krol M, et al. Supplemental Digital
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationThis article was published in an Elsevier journal. The attached copy is furnished to the author for non-commercial research and education use, including for instruction at the author s institution, sharing
More informationBinge Eating Disorder (B.E.D.) Discussion Guide. Making conversations with adults you suspect of having B.E.D. more comfortable and productive
B.E.D. Resource Kit Binge Eating Disorder (B.E.D.) Discussion Guide Making conversations with adults you suspect of having B.E.D. more comfortable and productive Two studies demonstrated that discussing
More informationA Comparison of Sequenced Individual and Group Psychotherapy for Patients with Bulimia Nervosa
REGULAR ARTICLE A Comparison of Sequenced Individual and Group Psychotherapy for Patients with Bulimia Nervosa Lauri Nevonen, PhD 1,2* Anders G. Broberg, PhD 3 ABSTRACT Objective: The current study examined
More informationDepression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol
Lindsay French PGY3 Depression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol dependence have complicated course of
More informationORIGINAL ARTICLE. Psychological Treatments of Binge Eating Disorder
ORIGINAL ARTICLE Psychological Treatments of Binge Eating Disorder G. Terence Wilson, PhD; Denise E. Wilfley, PhD; W. Stewart Agras, MD; Susan W. Bryson, MA, MS Context: Interpersonal psychotherapy (IPT)
More informationTreatment Quad Cities Eating Disorders Consortium
Treatment Quad Cities Eating Disorders Consortium James E. Mitchell, MD UND School of Medicine and Health Sciences Neuropsychiatric Research Institute ANOREXIA NERVOSA BULIMIA NERVOSA BINGE EATING DISORDER
More informationNIH Public Access Author Manuscript Behav Res Ther. Author manuscript; available in PMC 2012 October 1.
NIH Public Access Author Manuscript Published in final edited form as: Behav Res Ther. 2011 October ; 49(10): 714 717. doi:10.1016/j.brat.2011.06.006. Ecological Momentary Assessment of Bulimia Nervosa:
More informationHealing The Hunger Recognition and Treatment of Eating Disorders
Healing The Hunger Recognition and Treatment of Eating Disorders COPYRIGHT Copyright 2016 by Brian L. Bethel, PhD, LPCC-S, LCDC III, RPT-S Healing the Hunger, Recognition and Treatment of Eating Disorders.
More informationPregabalin As A Treatment for Generalized Anxiety Disorder. Ashley Storrs PGY III December 2, 2010
Pregabalin As A Treatment for Generalized Anxiety Disorder Ashley Storrs PGY III December 2, 2010 Background Information Approximately 18.1 percent of American adults 18 years or older have an anxiety
More informationA prospective, randomized placebo-controlled double-blind study of fluoxetine in patients with somatization disorder in two general medical clinics.
A prospective, randomized placebo-controlled double-blind study of fluoxetine in patients with somatization disorder in two general medical clinics. Emmy Ludwig A. Study Rationale and Purpose Somatoform
More informationfor anxious and avoidant behaviors.
Summary of the Literature on the Treatment of Anxiety Disorders in Children and Adolescents Sucheta D. Connolly, M.D.* Non-OCD anxiety disorders in youth are common and disabling, with 12-month prevalence
More informationCapturing clinically significant eating pathology in adolescence
Eur. J. Psychiat. Vol. 27, N. 2, (122-128) 2013 Keywords: Demoralization; DCPR; DSM-IV; Cluster analysis. Capturing clinically significant eating pathology in adolescence Rasmus Isomaa, PhD*, ** Anna-Lisa
More informationSummary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ
CT Registry ID#236 Page 1 Summary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ Title of Study: Fluoxetine: Fluoxetine versus Placebo in Adolescent Depressed Patients Investigator(s): This single-center
More informationBinge Eating Disorder and Night Eating Syndrome in Adults with Type 2 Diabetes
Binge Eating Disorder and Night Eating Syndrome in Adults with Type 2 Diabetes Kelly C. Allison,* Scott J. Crow, Rebecca R. Reeves, Delia Smith West, John P. Foreyt, Vicki G. DiLillo, Thomas A. Wadden,*
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationComparison of DSM-IV Versus Proposed DSM-5 Diagnostic Criteria for Eating Disorders: Reduction of Eating Disorder Not Otherwise Specified and Validity
CE ACTIVITY Comparison of DSM-IV Versus Proposed DSM-5 Diagnostic Criteria for Eating Disorders: Reduction of Eating Disorder Not Otherwise Specified and Validity Pamela K. Keel, PhD 1 * Tiffany A. Brown,
More informationKyle was a 22-year old, Caucasian, gay male undergraduate student in his junior year
Introduction and Background CASE CONCEPTUALIZATION Kyle was a 22-year old, Caucasian, gay male undergraduate student in his junior year at a large southeastern university. Kyle first presented for intake
More informationWeight suppression predicts weight gain during inpatient treatment of bulimia nervosa
Physiology & Behavior 87 (2006) 487 492 Weight suppression predicts weight gain during inpatient treatment of bulimia nervosa Michael R. Lowe a,b,, William Davis b, Dara Lucks a, Rachel Annunziato a, Meghan
More informationNIH Public Access Author Manuscript Int J Eat Disord. Author manuscript; available in PMC 2013 November 15.
NIH Public Access Author Manuscript Published in final edited form as: Int J Eat Disord. 2013 April ; 46(3):. doi:10.1002/eat.22115. What constitutes clinically significant binge eating? Association between
More informationIntroduction. Method. CM Grilo 1 * and RM Masheb 1
(2000) 24, 404±409 ß 2000 Macmillan Publishers Ltd All rights reserved 0307±0565/00 $15.00 www.nature.com/ijo in outpatients with binge eating disorder CM Grilo 1 * and RM Masheb 1 1 Yale Psychiatric Institute
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationStudy Center(s): The study was conducted at 39 study sites in Japan.
SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01
More informationDo Adherence Variables Predict Outcome in an Online Program for the Prevention of Eating Disorders?
Journal of Consulting and Clinical Psychology Copyright 2008 by the American Psychological Association 2008, Vol. 76, No. 2, 341 346 0022-006X/08/$12.00 DOI: 10.1037/0022-006X.76.2.341 BRIEF REPORTS Do
More informationThe treatment of postnatal depression: a comprehensive literature review Boath E, Henshaw C
The treatment of postnatal depression: a comprehensive literature review Boath E, Henshaw C Authors' objectives To evalute treatments of postnatal depression. Searching MEDLINE, PsycLIT, Sociofile, CINAHL
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPRIMARY CARE PSYCHIATRY VOL. 9, NO. 1, 2003, 15 20
PRIMARY CARE PSYCHIATRY VOL. 9, NO. 1, 2003, 15 20 10.1185/135525703125002342 2003 LIBRAPHARM LIMITED Use of St John s wort (Hypericum perforatum L) in members of a depression self-help organisation: a
More informationPharmacists in Medication Adherence in Psychiatric Patients
Pharmacists in Medication Adherence in Psychiatric Patients Mamta Parikh, PharmD, BCPS, BCPP Assistant Professor, Clinical and Administrative Sciences Notre Dame of Maryland University School of Pharmacy
More informationIMPLICATIONS OF THE DSM-5 REVISIONS ON THE DIAGNOSIS AND TREATMENT OF EATING DISORDERS
IMPLICATIONS OF THE DSM-5 REVISIONS ON THE DIAGNOSIS AND TREATMENT OF EATING DISORDERS PRESENTED BY KARYN L. SCHER, PH.D. 6/18/14 PENNSYLVANIA PSYCHOLOGICAL ASSOCIATION ANNUAL CONVENTION ABSTRACT Eating
More information2005, Editrice Kurtis
ORIGINAL RESEARCH PAPER Vol. 10: 51-58, March 2005 A short-term cognitive group treatment program gives substantial weight reduction up to 18 months from the end of treatment. A randomized controlled trial
More informationThe strength of a multidisciplinary approach towards students with an eating problem.
The strength of a multidisciplinary approach towards students with an eating problem. Sigrid Schoukens, psychologist Maura Sisk, general practitioner Student Health Center, KULeuven EUSUSHM CONGRESS 2017
More informationBinge and Emotional Eating in obese. subjects seeking weight loss treatment.
Binge and Emotional Eating in obese subjects seeking weight loss treatment. Running Title: Binge and Emotional Eating in obesity Valdo Ricca a, Giovanni Castellini a, Carolina Lo Sauro a, Claudia Ravaldi
More informationCounseling College Women Experiencing Eating Disorder Not Otherwise Specified: A Cognitive Behavior Therapy Model
Counseling College Women Experiencing Eating Disorder Not Otherwise Specified: A Cognitive Behavior Therapy Model Sarina: 1. Although the Counseling College Women article suggests utilizing CBT to treat
More information